Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (NCT05053152)
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Who can join: Review the eligibility criteria below.
Location: Cancer Center at Saint Joseph's — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (245 Sites)
Showing the first 25 of 245 sites.
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Marin General Hospital — Greenbrae, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Memorial Medical Center — Modesto, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Sutter Medical Center Sacramento — Sacramento, California
- Sutter Pacific Medical Foundation — Santa Rosa, California
- Sutter Solano Medical Center/Cancer Center — Vallejo, California
- UCHealth University of Colorado Hospital — Aurora, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- AdventHealth Porter — Denver, Colorado
- Shaw Cancer Center — Edwards, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- Banner North Colorado Medical Center — Greeley, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- UCHealth Highlands Ranch Hospital — Highlands Ranch, Colorado
- AdventHealth Littleton — Littleton, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oligometastatic Prostate Carcinoma
Explore by condition: All Oligometastatic Prostate Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.